Filing Flows › Health Care › Cerenome (CNSY)
Cerenome (CNSY) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Cerenome (CNSY) Q2 2026 earnings results →
Q2 2026 Revenue down 70% year over year to $411K
Cerenome made $411K in Q2 2026 (-70% Y/Y). Operating margin n/m, net loss $9.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $411K in Q2 2026, down 70% year over year and down 60% from the previous quarter.
Operating costs exceeded revenue by $9.1M, an operating margin of -2203.6%. Total costs grew 223% against a revenue fall of 70%. The fastest-growing cost line was Research & development (+242%). The quarter ended with a net loss of $9.0M, wider than the previous quarter's $6.9M loss.
Operating cash flow was −$7.1M. Non-cash charges added back $137K of depreciation and amortization and $830K of share-based compensation. Working capital and other items added $907K. Capital expenditures of $499K exceeded it, leaving free cash flow of −$7.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $411K | -70% | n/m | −$9.0M | −$7.1M |
| Q1 2026 | 10-Q | May 15, 2026 | $1.0M | -3% | -692.5% | −$6.9M | −$6.2M |
| Q4 2025 | 10-K | Mar 12, 2026 | $1.4M | -3% | -420.0% | −$5.7M | −$6.3M |
| Q3 2025 | 10-Q | Oct 30, 2025 | $1.4M | -4% | -320.8% | −$4.4M | −$2.5M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.4M | +9% | -110.6% | $5.2M | −$5.8M |
| Q1 2025 | 10-Q | May 30, 2025 | $1.1M | -37% | -333.9% | −$17.4M | −$6.2M |
| Q4 2024 | 10-K | Mar 31, 2025 | $1.4M | — | -276.2% | −$3.9M | −$1.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data and artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
In its own words, from its 8-K, filed Aug 14, 2026.
Cerenome against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -70% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CNSY Cerenome | Q2 2026 | $411K | -70% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Cerenome 10-Q on SEC EDGAR · CIK 1095981 · Surgical & Medical Instruments & Apparatus
13F: who owns CNSY and who is buying
More on CNSY
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results